ArticleThe Journal of biological chemistry2009
Control of alternative splicing by signal-dependent degradation of splicing-regulatory proteins.
Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- The conserved alternative splicing factor caper regulates neuromuscular phenotypes during development and aging.Developmental biology · 2021Article
- Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1.Cancer & metabolism · 2021Article
- Glycogen synthase kinase-3 and alternative splicing.Wiley interdisciplinary reviews. RNA · 2018Review
- BIM and NOXA are mitochondrial effectors of TAF6δ-driven apoptosis.Cell death & disease · 2018Article
- Hippo signaling promotes JNK-dependent cell migration.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.BMC molecular biology · 2016Article
- The RNA Splicing Response to DNA Damage.Biomolecules · 2015Review
- A functional screen reveals an extensive layer of transcriptional and splicing control underlying RAS/MAPK signaling in Drosophila.PLoS biology · 2014Article
- Half pint/Puf68 is required for negative regulation of splicing by the SR splicing factor Transformer2.RNA biology · 2013Article
- RNA splicing: a new player in the DNA damage response.International journal of cell biology · 2013Review
- The cardiotonic steroid digitoxin regulates alternative splicing through depletion of the splicing factors SRSF3 and TRA2B.RNA (New York, N.Y.) · 2012Article
- Upon the tightrope in prostate cancer: two acrobats on the same tightrope to cross the finishline.Molecular and cellular biochemistry · 2012Review
- Regulated functional alternative splicing in Drosophila.Nucleic acids research · 2012Review
- Degrade, move, regroup: signaling control of splicing proteins.Trends in biochemical sciences · 2011Review
- Verification of alternative splicing variants based on domain integrity, truncation length and intrinsic protein disorder.Nucleic acids research · 2011Article
- The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.The Journal of biological chemistry · 2011Article
- Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.PloS one · 2009Article
- Aging--RNA in development and disease.Wiley interdisciplinary reviews. RNAReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alternative pre-mRNA splicing is a major gene expression regulatory mechanism in metazoan organisms. Proteins that bind pre-mRNA elements and control assembly of splicing complexes regulate utilization of pre-mRNA alternative splice sites. To understand how signaling pathways impact this mechanism, an RNA interference screen in Drosophila S2 cells was used to identify proteins that regulate TAF1 (TBP-associated factor 1) alternative splicing in response to activation of the ATR (ATM-RAD3-related) signaling pathway by the chemotherapeutic drug camptothecin (CPT). The screen identified 15 proteins that, when knocked down, caused the same change in TAF1 alternative splicing as CPT treatment. However, combined RNA interference and CPT treatment experiments indicated that only a subset of the identified proteins are targets of the CPT-induced signal, suggesting that multiple independent pathways regulate TAF1 alternative splicing. To understand how signals modulate the function of splicing factors, we characterized one of the CPT targets, Tra2 (Transformer-2). CPT was found to down-regulate Tra2 protein levels. CPT-induced Tra2 down-regulation was ATR-dependent and temporally paralleled the change in TAF1 alternative splicing, supporting the conclusion that Tra2 directly regulates TAF1 alternative splicing. Additionally, CPT-induced Tra2 down-regulation occurred independently of new protein synthesis, suggesting a post-translational mechanism. The proteasome inhibitor MG132 reduced CPT-induced Tra2 degradation and TAF1 alternative splicing, and mutation of evolutionarily conserved Tra2 lysine 81, a potential ubiquitin conjugation site, to arginine inhibited CPT-induced Tra2 degradation, supporting a proteasome-dependent alternative splicing mechanism. We conclude that CPT-induced TAF1 alternative splicing occurs through ATR-signaled degradation of a subset of splicing-regulatory proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.